ArticleJournal of translational medicine2021
Fe
Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Landscape and evolutionary trends of nanotechnology in cancer radiosensitization.Discover nano · 2026Review
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- Magnetic thermoradiotherapy for lung cancer: evaluation in A549-based preclinical models.Frontiers in oncology · 2026Article
- Article
- Cisplatin-encapsulated zeolitic imidazolate framework-8 nanosystem enhanced radiosensitivity of non-small cell lung cancer.Scientific reports · 2025Article
- Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling.Cell death & disease · 2025Article
- Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement.International journal of pharmaceutics: X · 2024Review
- Application of nano-radiosensitizers in non-small cell lung cancer.Frontiers in oncology · 2024Review
- Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer.Research (Washington, D.C.) · 2024Review
- Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients.BMC cancer · 2023Article
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.International journal of molecular sciences · 2022Review
- Efficacy and Safety of Nanoadministration in the Treatment of Non-Small-Cell Lung Cancer Is Good to Some Extent: A Systematic Review and Meta-Analysis.Journal of oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is the mainstay treatment for lung adenocarcinoma, yet remains highly susceptible to resistance. Fe
methodsFe
resultsNPs were successfully prepared and characterized. BIRC5 expression levels were augmented in tissues of lung cancer patients. Fe
conclusionFindings obtained in our study indicated that Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.